← FDA Drug Approvals (Drugs@FDA)
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: LAURUS · Approved 2026-03-04
Drug application
- FDA Application #
ANDA220232- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
- Generic name
- EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
- Active ingredients
- EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Sponsor
- LAURUS
- Manufacturer
- Laurus Labs Limited
- First approval
- 2026-03-04
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown